Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RXII

RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

RXi Pharmaceuticals logo

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

Advanced Chart

Key Stats

Today's Range
$2.33
$2.49
50-Day Range
$0.36
$0.50
52-Week Range
$0.31
$7.70
Volume
84,045 shs
Average Volume
1.73 million shs
Market Capitalization
$10.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RXII Stock News Headlines

Rex International Holding Ltd (RXI.SG)
Galena's Breast Cancer Vaccine Doomed to Fail
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Q4 2022 Catalyst Pharmaceuticals Inc Earnings Call
iShares Global Consumer Discretionary ETF (RXI)
See More Headlines

RXII Stock Analysis - Frequently Asked Questions

RXi Pharmaceuticals Co. (NASDAQ:RXII) released its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.02 million. RXi Pharmaceuticals had a negative trailing twelve-month return on equity of 412.15% and a negative net margin of 4,990.20%.

RXi Pharmaceuticals shares reverse split before market open on Monday, January 8th 2018.The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that RXi Pharmaceuticals investors own include Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Endologix (ELGX), Auris Medical (EARS), Protalix BioTherapeutics (PLX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
8/14/2018
Today
7/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RXII
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.45 million
Net Margins
-4,990.20%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10 thousand
Price / Cash Flow
N/A
Book Value
$0.77 per share
Price / Book
3.12

Miscellaneous

Free Float
N/A
Market Cap
$10.51 million
Optionable
Not Optionable
Beta
2.07
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:RXII) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners